Trial Profile
Effect of Aflibercept (Eylea) in the Management of Bevacizumab (Avastin) Resistant Diabetic Macular Edema
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Mar 2019
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- 23 Mar 2017 Planned number of patients changed from 31 to 40.
- 23 Mar 2017 Status changed from not yet recruiting to recruiting.
- 07 Oct 2016 New trial record